Artemether-d₃is intended for use as an internal standard for the quantification of artemether by GC- or LC-MS. Artemether is an antiparasitic agent and a derivative of artemisinin .¹It induces mortality in adult wild-type andpfatp6-mutantP. falciparumbut the efficacy is decreased in the mutants (IC₅₀s = 8.2 and 13.5 nM, respectively).²Artemether reduces parasitemia inP. falciparum-infected monkeys andP. berghei-infected mice with 50% curative dose (CD₅₀) values of 7.1 and 55 mg/kg, respectively.³It also reduces the worm burden ofS. mansonitrematodes in mice when used at doses ranging from 200 to 500 mg/kg.¹Formulations containing artemether have been used in the treatment of malaria.

1.Xiao, S.H., and Catto, B.A.In vitro and in vivo studies of the effect of artemether on Schistosoma mansoniAntimicrob. Agents Chemother.33(9)1557-1562(1989) 2.Pillai, D.R., Lau, R., Khairnar, K., et al.Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers returning with Plasmodium falciparum infectionsMalar. J.11131(2012) 3.Shmuklarsky, M.J., Klayman, D.L., Milhous, W.K., et al.Comparison of β-artemether and β-arteether against malaria parasites in vitro and in vivoAm. J. Trop. Med. Hyg.48(3)377-384(1993)